MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia with Lewy bodies (DLB)"

  • 2023 International Congress

    Longitudinal free-water changes in dementia with Lewy bodies

    S. Chiu, R. Chen, W. Wang, M. Armstrong, B. Boeve, K. Kantarci, D. Vaillancourt (Gainesville, USA)

    Objective: To characterize longitudinal diffusion microstructural changes in individuals with dementia with Lewy bodies (DLB). Background: Diffusion-weighted MRI (dMRI) examines tissue microstructure integrity in vivo.…
  • 2023 International Congress

    T1 MRI reveals differential hippocampal atrophy in Lewy body disorders with and without Alzheimer’s copathology

    J. Cohen, J. Phillips, S. Das, E. Rhodes, K. Cousins, P. Yushkevich, D. Wolk, D. Weintraub, D. Irwin, C. Mcmillan (Philadelphia, USA)

    Objective: Determine whether MRI can identify differences in hippocampal volume between patients with Lewy body disorders with and without Alzheimer's copathology, and whether these differences…
  • 2023 International Congress

    Topography of cholinergic vulnerability correlates of PIGD motor deficits in DLB and PSP: A [18F]-FEOBV PET study

    P. Kanel, T. Brown, S. Roytman, J. Barr, C C. Spears, N. Bohnen (Ann Arbor, USA)

    Objective: To understand the relationship between cholinergic vulnerability and Postural Instability and Gait Disturbances (PIGD) motor features in dementia with Lewy bodies (DLB), and progressive…
  • 2023 International Congress

    RT-QuIC for detection of pathological α-synuclein in the olfactory mucosa and CSF of Parkinson’s disease patients

    V. Tommasini, M. Bongianni, M. Catalan, D. Perra, P. Polverino, C. Bertolotti, R. Baruca, G. Bellavita, L. Antonutti, G. Zanusso, P. Manganotti (Trieste, Italy)

    Objective: To investigate the proficiency of RT-QuIC in detecting the presence of misfolded α-synuclein (α-syn) on the olfactory mucosa (OM) and CSF of patients with…
  • 2023 International Congress

    Quetiapine for the treatment of psychosis in dementia with Lewy bodies: a systematic review.

    M. Giusti, PL. Silva, G. Bolner, C. Menegon, MF. Felippe, G. Herwig, A. Rossato, EG. Almeida, M. Rosa, CR. Rieder (Porto Alegre, Brazil)

    Objective: Perform a systematic review of the literature about the efficacy of quetiapine in the treatment of psychosis in patients with Lewy’s Body Dementia. Background:…
  • 2023 International Congress

    Falls in Mild Cognitive Impairment with Lewy bodies (MCI-LB).

    E. Lirani Silva, S. Waite, C. Hamilton, P. Donaghy, J. O'Brien, J. Taylor, J. Lloyd, L. Allan, M. Firbank, A. Thomas, A. Yarnall (Newcastle, United Kingdom)

    Objective: to identify clinical, physical activity and mobility measures that differentiate patients with mild cognitive impairment with Lewy bodies (MCI-LB) fallers and non-fallers from cognitively…
  • 2023 International Congress

    Clinical characteristics of patients with dementia with Lewy bodies followed in a movement disorder clinic

    AS. Jakobsson, L. Salvesen, AM. Hejl (Copenhagen, Denmark)

    Objective: To describe the clinical phenotype of the subgroup of patients with Dementia with Lewy bodies (DLB) followed in a movement disorder setting rather than…
  • 2023 International Congress

    Comparative efficacy of pharmacological cognitive treatments in Parkinson’s disease and Dementia of Lewy Bodies: systemic review & network meta-analysis

    F. Al Hajraf, S. Manohar, M. Hu (Oxford, United Kingdom)

    Objective: The aim of this study is to evaluate, compare and rank the currently available pharmacological cognitive treatments. Background: Treating cognitive impairment in Parkinson’s disease…
  • 2023 International Congress

    Keeping patients out of care facilities— clozapine rescues Parkinson’s patients with troublesome psychosis unresponsive to quetiapine and pimavanserin.

    J. Iseringhausen, G. Riboldi, K. Astudillo, S. Frucht (New York, USA)

    Objective: We describe a single-center cohort of Parkinson patients in crisis with troublesome psychosis unresponsive to quetiapine and pimavanserin, who were rescued by treatment with…
  • 2023 International Congress

    Combined GWAS of Dementia with Lewy Bodies, REM-Sleep Behavior Disorder, Parkinson’s Disease and Alzheimer’s Disease

    P. Saini, E. Yu, L. Krohn, Z. Gan-Or (Montreal, Canada)

    Objective: To identify genetic variants that are either shared between or specific for Dementia with Lewy Bodies (DLB), REM Behavior Disorder (RBD), Parkinson’s disease (PD)…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 23
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29509 (not found)
  • Expanding the Phenotype of KCNA2 Mutation: Tics and Stereotypies
  • #22661 (not found)
  • #29591 (not found)
  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley